The United States Food and Drug Administration (FDA) has granted tentative approval to the first generic version of Lenacapavir, a long-acting injectable medicine used to prevent HIV infection. The generic version has been developed by India’s Dr. Reddy’s Laboratories. This development is an important step towards making HIV prevention more affordable and accessible, particularly in low- and middle-income countries. The medicine requires only two injections per year, offering an alternative to daily HIV prevention pills.
Why in News?
On 2 November 2026, India’s pharmaceutical company Dr. Reddy’s Laboratories received tentative approval from the US FDA for its generic version of Lenacapavir.
The approval makes Dr. Reddy’s the first of six licensed generic manufacturers to achieve this regulatory milestone for the long-acting HIV prevention injection.
The generic medicine is expected to cost approximately US$40 per person per year and will be made available in 120 low- and middle-income countries under a voluntary licensing agreement.
What is Lenacapavir?
Lenacapavir is a long-acting antiretroviral medicine developed by Gilead Sciences for HIV prevention and treatment.
It works by targeting the HIV capsid, a protein shell that protects the virus’s genetic material and plays an important role in its replication.
Important features of Lenacapavir include:
- Drug Type: Long-acting antiretroviral medicine.
- Purpose: Prevention of HIV infection.
- Administration: Subcutaneous injection.
- Dosage Schedule: Twice a year (every six months).
- Original Developer: Gilead Sciences.
- Generic Manufacturer: Dr. Reddy’s Laboratories.
- Brand Name: Yeztugo (original HIV prevention product in the US).
Key Details of FDA Approval
The major details of this development are given below:
| Particular | Details |
| Drug | Lenacapavir |
| Generic manufacturer | Dr. Reddy’s Laboratories |
| Regulatory authority | US FDA |
| Approval date | 2 November 2026 |
| Original developer | Gilead Sciences |
| Expected generic price | US$40 per person per year |
| Target countries | 120 low- and middle-income countries |
| Dosage | Two injections annually |
| Main purpose | HIV prevention |
Note: The FDA has granted tentative approval. This is a regulatory milestone that allows the generic to move towards procurement and availability in eligible markets, but it does not mean unrestricted commercial sale in the United States.
How Does Lenacapavir Help Prevent HIV?
Lenacapavir is used as Pre-Exposure Prophylaxis (PrEP).
PrEP refers to the use of HIV-prevention medicines by people who do not have HIV but may be at risk of infection.
Its major benefits include:
- Long-Acting Protection: It provides an alternative to taking HIV prevention tablets every day.
- Twice-Yearly Administration: Only two injections are required annually.
- High Effectiveness: Clinical trials have demonstrated very high effectiveness in preventing HIV infection.
- Improved Accessibility: Affordable generic production can make HIV prevention more accessible in developing countries.
Lenacapavir is a preventive medicine, not a cure for HIV. HIV testing and medical supervision are necessary before and during its use.
Role of Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana.
The company received a voluntary licensing agreement from Gilead Sciences to manufacture and commercialise generic Lenacapavir in 120 countries.
The development received financial, technical and regulatory support from three major organisations:
- Unitaid: Supports affordable access to essential health products.
- Clinton Health Access Initiative (CHAI): Works to improve access to healthcare in developing countries.
- Wits RHI: Wits Reproductive Health and HIV Institute, based at the University of the Witwatersrand, South Africa.
Under the agreement, the generic version is expected to be supplied at approximately US$40 per person annually. Initial supplies are expected before the end of 2026, with broader availability planned for 2027.
Significance for Low- and Middle-Income Countries
The development of generic Lenacapavir is important for global public health.
- Affordable Healthcare: Lower prices can improve access to HIV prevention medicines.
- HIV Prevention: Long-acting injections provide another option for people at risk of HIV infection.
- Healthcare Accessibility: Developing countries can benefit from improved access to modern preventive medicines.
- Indian Pharmaceutical Industry: It highlights India’s role in developing and manufacturing affordable generic medicines.
- Global HIV Control: Wider access to preventive medicines can support international efforts to reduce new HIV infections.
What is HIV and PrEP?
HIV (Human Immunodeficiency Virus): HIV is a virus that attacks the body’s immune system, particularly CD4 cells. If left untreated, it can lead to AIDS (Acquired Immunodeficiency Syndrome).
PrEP (Pre-Exposure Prophylaxis): PrEP is a preventive approach in which HIV-negative individuals use medicines to reduce their risk of acquiring HIV.
It is an important component of global HIV prevention strategies.
Conclusion
The FDA’s tentative approval of generic Lenacapavir developed by Dr. Reddy’s Laboratories is an important milestone in affordable HIV prevention. Its twice-yearly injection schedule and expected annual cost of US$40 could improve access to preventive healthcare in 120 low- and middle-income countries. The development also demonstrates the growing contribution of India’s pharmaceutical industry to global public health.
